logo

For the Inventor, By the Inventor

Uppsala, Sweden

Orexo Ab


USPTO Granted Patents = 40

% Expired Patents = 32.5



Trademarks = 11

Forward Citations = 202

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Anders Pettersson (15 out of 23 patents)

silverMedal Andreas Fischer (14 out of 16 patents)

bronzeMedal Jonas Sävmarker (10 out of 11 patents)

4.  Robert Rönn (10 out of 11 patents)

5.  Henri Doods (4 out of 76 patents)

6.  Raimund Kuelzer (4 out of 27 patents)

7.  Christer Nystrom (4 out of 9 patents)

8.  Roland Pfau (4 out of 32 patents)

9.  Dirk Stenkamp (4 out of 50 patents)

10.  Barbro Johansson (3 out of 3 patents)

11.  Emil Schwan (3 out of 3 patents)

12.  Henning Priepke (3 out of 47 patents)

13.  Klaus Klinder (3 out of 19 patents)

14.  Juergen Mack (3 out of 19 patents)

15.  Kirsten Arndt (3 out of 29 patents)


Core Competencies:
Pharmaceutical Composition
Intranasal Administration
Nasal Delivery
Opioid Dependence
Abuse-Resistant Composition
Alfentanil Composition
Acute Pain Treatment
Insomnia Treatment
Anti-Inflammatory Agents
Gastric Acid Secretion Inhibition
Drug Delivery
Depression Control

40 patents:

1. 12472154 - Pharmaceutical composition comprising adrenaline (2025-11-18),
2. 12357573 - Pharmaceutical composition for drug delivery (2025-07-15),
3. 12303472 - Pharmaceutical device for use in intranasal administration (2025-05-20),
4. 12268684 - Pharmaceutical composition for nasal delivery (2025-04-08),
5. 12138259 - Method of controlling depression in subjects treated for opioid dependence (2024-11-12),
6. 11986472 - Method of controlling alcohol consumption in subjects treated for opioid dependence (2024-05-21),
7. 11957647 - Pharmaceutical composition comprising adrenaline (2024-04-16),
8. 11883392 - Pharmaceutical composition for nasal delivery (2024-01-30),
9. 11737980 - Pharmaceutical composition for drug delivery (2023-08-29),
10. 11617746 - Method of controlling depression in subjects treated for opioid dependence (2023-04-04),
11. 11433066 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2022-09-06),
12. 11020388 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2021-06-01),
13. 11020387 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2021-06-01),
14. 10946010 - Abuse-resistant pharmaceutical composition for the treatment of opioid dependence (2021-03-16),
15. 10898480 - Pharmaceutical composition for nasal delivery (2021-01-26),
Orexo is a Swedish pharmaceutical company focused on developing innovative treatments for addiction and pain management. With a vision to improve the lives of patients, Orexo combines pharmaceutical expertise with digital therapeutics to provide comprehensive solutions. Their portfolio includes FDA-approved medications for opioid addiction and pain, as well as proprietary digital therapy platforms. Orexo's commitment to research, development, and patient-centric approach has made them a leader in the field of addiction and pain management.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Orexo Ab
40 Patents

#7 in Uppsala

#174 in Sweden

#17,015 in the World

Uppsala, SE
Uppsala, Sweden

Orexo Ab

Forward Citations = 202

25 inventors:

goldMedal Anders Pettersson (15 out of 23 patents)

silverMedal Andreas Fischer (14 out of 16 patents)

bronzeMedal Jonas Sävmarker (10 out of 11 patents)

4.  Robert Rönn (10 out of 11 patents)

5.  Henri Doods (4 out of 76 patents)

Please report any incorrect information to [email protected]
Loading…